These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20218354)

  • 1. [Influenza vaccines adjuvants--contemporary state].
    Vasil'ev IuM
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (1):100-10. PubMed ID: 20218354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Avian influenza vaccines].
    Vasil'ev IuM
    Vopr Virusol; 2008; 53(6):4-15. PubMed ID: 19172900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvanted influenza vaccines.
    Principi N; Esposito S
    Hum Vaccin Immunother; 2012 Jan; 8(1):59-66. PubMed ID: 22252004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race is on for flu vaccine.
    Wadman M
    Nature; 2005 Nov; 438(7064):23. PubMed ID: 16267526
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of different chemical adjuvants on an avian influenza H6 DNA vaccine in chickens.
    Shan S; Fenwick S; Ellis T; Poinern E; Edwards J; Le X; Jiang Z
    Avian Pathol; 2016 Dec; 45(6):649-656. PubMed ID: 27314157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase.
    Schmidt R; Holznagel E; Neumann B; Alex N; Sawatsky B; Enkirch T; Pfeffermann K; Kruip C; von Messling V; Wagner R
    Vaccine; 2016 Oct; 34(44):5329-5335. PubMed ID: 27616472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic evaluation of 10 different adjuvants for use in vaccines for chickens against highly pathogenic avian influenza virus.
    Lone NA; Spackman E; Kapczynski D
    Vaccine; 2017 Jun; 35(26):3401-3408. PubMed ID: 28511853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ADJUVANTED INFLUENZA VACCINES: DATA FROM DIRECT COMPARATIVE STUDIES].
    Chernikova MI; Vasiliev YM
    Zh Mikrobiol Epidemiol Immunobiol; 2015; (5):88-102. PubMed ID: 26829860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection bias in the comparison between adjuvanted and unadjuvanted influenza vaccine effectiveness.
    De Serres G
    Vaccine; 2014 Nov; 32(49):6596. PubMed ID: 24380683
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjuvanted influenza vaccines.
    Even-Or O; Samira S; Ellis R; Kedar E; Barenholz Y
    Expert Rev Vaccines; 2013 Sep; 12(9):1095-108. PubMed ID: 24053401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.
    Jones T
    Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chitosan as an adjuvant for inactivated vaccines against avian influenza viruses].
    Gendon IuZ; Vasil'ev IuM; Markushin SG; Akopova II; Koptiaeva IB; Krivtsov GG
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (2):40-7. PubMed ID: 19459476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines against seasonal and avian influenza: recent advances.
    Osterhaus AD; Poland GA
    Vaccine; 2008 Sep; 26 Suppl 4():D1-2. PubMed ID: 19230151
    [No Abstract]   [Full Text] [Related]  

  • 16. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
    Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
    Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
    Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
    Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
    Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
    Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Review of materials of VI International Conference "Options for the Control for Influenza"].
    Nekrasov AV; Puchkova NG
    Zh Mikrobiol Epidemiol Immunobiol; 2008; (3):115-20. PubMed ID: 18595477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.